XML 49 R31.htm IDEA: XBRL DOCUMENT v3.25.4
Revenue (Tables)
 12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes our revenue recognized in our consolidated statements of operations:
202520242023
Net product revenue$60,958 $40,748 $28,814 
Collaboration and other revenue4,221 4,295 5,310 
Revenue$65,179 $45,043 $34,124 
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product:
U.S.Outside U.S.
202520242023202520242023
Cardiometabolic Health:
Mounjaro$13,651 $8,950 $4,834 $9,315 $2,590 $329 
Zepbound(1)
13,484 4,926 176 58 — — 
Trulicity2,914 3,694 5,433 1,362 1,560 1,699 
Jardiance(2)
1,582 1,598 1,600 1,849 1,743 1,144 
Other cardiometabolic health2,233 2,682 2,738 1,773 1,778 1,715 
Total cardiometabolic health33,864 21,850 14,781 14,357 7,671 4,887 
Oncology:
Verzenio3,464 3,421 2,509 2,259 1,886 1,354 
Other oncology1,888 1,615 1,288 1,765 1,831 1,507 
Total oncology5,352 5,036 3,797 4,024 3,717 2,861 
Immunology:
Taltz2,333 2,152 1,832 1,230 1,108 928 
Other immunology631 306 226 1,053 827 812 
Total immunology2,964 2,458 2,058 2,283 1,935 1,740 
Neuroscience997 780 696 394 694 2,183 
Other304 251 459 639 652 663 
Revenue$43,481 $30,375 $21,791 $21,698 $14,668 $12,333 
(1) Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the U.S.
(2) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
The following table summarizes revenue by geographical area:
202520242023
Revenue(1):
U.S.$43,481 $30,375 $21,791 
Europe11,558 6,921 6,175 
Japan2,132 1,815 1,673 
China1,951 1,660 1,540 
Rest of world6,057 4,271 2,946 
Revenue$65,179 $45,043 $34,124 
(1) Revenue is attributed to the countries based on the location of the customer or other party